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Long-Term Follow-Up After Cryothermic Ostial
Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation
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Benoit Ghaye, MD,† Suzanne Philippens, RN,* Hein J. J. Wellens, MD, PHD, FACC,‡
Luz-Maria Rodriguez, MD, PHD, FACC*
Maastricht, the Netherlands; and Liége, Belgium
Objectives This study was designed to evaluate the long-term effect of segmental pulmonary vein (PV) cryoablation in pa-
tients with recent-onset paroxysmal atrial fibrillation (PAF).
Background Patients with PAF have more triggers to initiate and less substrate to sustain atrial fibrillation (AF). Elimination
of the potential initiators alone may be sufficient to abolish the arrhythmia.
Methods Patients with PAF were prospectively recruited from July 2001 to July 2005. If the triggers for AF were identified,
PV cryoisolation of the arrhythmogenic vein(s) was performed. Otherwise, all PVs were isolated.
Results Seventy patients with minimal or no heart disease (54 men; age 40  10 years) were enrolled. The duration of
AF was 4  1 year. The left ventricular ejection fraction and left atrial size were 59  8% and 41  5 mm, re-
spectively. An arrhythmogenic PV was found in 10 patients (14%). Complications occurred in 3 patients (4%). No
PV stenosis or esophageal injury was detected during a mean follow-up of 33  15 months. Thirty-four patients
(49%) achieved complete success (no AF and no antiarrhythmic drugs [AAD]); 15 patients (22%) had no recur-
rences with AAD; and 8 patients (11%), still with sporadic bursts of AF, improved 50% with AAD. Overall, 82%
of the patients benefited from the procedure. Patients in whom the arrhythmogenic PV was identified and iso-
lated had no recurrences.
Conclusions Pulmonary vein cryoisolation is effective in 82% of patients with recent-onset PAF during a mean follow-up of
33  15 (range 15 to 60) months. If the arrhythmogenic PV is identified and isolated, the long-term outcome is
excellent, indicating no need to isolate all PVs. (J Am Coll Cardiol 2008;51:850–5) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.065t
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ctrial fibrillation (AF) is a disease with different stages. In
arly stages, paroxysmal and nonsustained episodes are the
ule (1,2). In this stage, the triggers, mostly located in the
ulmonary veins (PV), are the main culprit of AF (3). Over
ime, atrial remodeling starts to occur, and more substrate
ecomes available to sustain longer episodes (4). Therefore,
elf-perpetuation of AF (AF begets AF) leads to the idea
hat a treatment strategy employed early in the disease
ould be more likely to succeed.
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rom CryoCor. Dr. Wellens is a member of the Advisory Board of CryoCor. Drs.
oreira and Manusama contributed equally to this study. Hugh Caulkins, MD,
ACC, served as the Guest Editor for this article.d
Manuscript received June 25, 2007; revised manuscript received July 27, 2007,
ccepted August 17, 2007.The actual ablative techniques are intended to eliminate
he triggers (ostial PV isolation 1 by 1 or 2 by 2) and/or to
odify the substrate. A technique that modifies the sub-
trate consists of the creation of multiple lines in both atria
5). Adding extensive left atrial linear ablation, although
eported to improve overall success rates in a group of
atients with more advanced stages of AF, has increased
orbidity and mortality (including iatrogenic left atrial
utter, phrenic nerve paralysis, and left atrial-to-esophageal
stula, which is almost universally fatal) (6–8). Many
atients with AF and structurally normal hearts are now
requently referred for ablation. In this group, empiric
xtensive left atrial ablation may not be the best approach
ecause the long-term risk of such extensive lesions is
nknown.
Cryothermy has been shown to have some inherent
dvantages over radiofrequency (RF) ablation. The absence
f pulmonary vein stenosis is one advantage (9). But despite
ryothermy’s benefits, the great majority of AF ablation is
one using RF (10). Our study, OPIPAF (Ostial Pulmo-
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esigned to evaluate the effect of a more localized ablation
trategy using cryothermy in patients with PAF in the early
tages of the disease.
ethods
eventy patients with drug-refractory, symptomatic PAF
ere enrolled prospectively from July 2001 to July 2006.
The screening protocol consisted of a review of Holter
ecordings, daily transtelephonic telemetry (TTM), the
umber of failed antiarrhythmic drugs (AAD), functional
apacity, type of AF, and imaging studies to exclude silent
yocardial ischemia. Inclusion criteria required the follow-
ng: 1) symptomatic PAF; 2) duration of PAF 5 years; 3)
ge 65 years; 4) lone AF or minimal heart disease; and 5)
eft atrial size 40 mm and no exposure to amiodarone.
All subjects were given a transtelephonic event recorder
nd instructed to use it daily (preferably at the same time)
nd when they had symptoms. This monitoring started 30
ays before and continued up to day 180 after pulmonary
ein isolation (PVI). From then on, a Holter monitor was
sed during clinic visits (1, 3, 6, 9, and 12 months) or when
atients had symptoms.
A baseline contrast-enhanced spiral computed tomogra-
hy (CT) scan of the thorax with 3-dimensional reconstruc-
ion of the heart was performed within 1 month before the
blation procedure and evaluated blindly by the same
adiologist who performed the follow-up study (B.G.).
All the patients in the study signed a written consent
orm that was approved by the local ethics committee.
efore PVI, all patients were orally anticoagulated to a
herapeutic international normalized ratio of 2 to 3 for at
east 3 weeks and up to 3 months after ablation. All AAD
ere stopped 5 days before PVI and restarted immediately
hereafter. Transesophageal echocardiogram (TEE) was
erformed during the procedure to exclude left atrial throm-
us and to aid in the transeptal puncture.
V cryoisolation. All patients were studied in the fasting
tate without sedation, except if external cardioversion was
eeded (when small doses of midazolam were used). Inter-
al cardioversions were done without sedation. Those pa-
ients presenting in AF while in the catheterization room
ere converted to sinus rhythm by internal or external
ardioversion.
During the procedure (but after the transseptal punc-
ures), intravenous heparin was given as a 100-IU/kg
olus dose followed by boluses of 5,000 IU every 1.5 h if
eeded to keep an activated clotting time 300 s. A
ecapolar catheter was positioned in the distal coronary
inus and a quadripolar catheter in the His bundle region
ia the femoral route. Double trans-septal catheterization
as performed under fluoroscopic and transesophageal
uidance.
Left atrial angiography was performed after adenosinedministration (11) to visualize the ostia of the pulmonary veins. Together with the left
trial angiography, we used the
avX system (Endocardial Solu-
ions, St. Jude Medical Inc., St.
aul, Minnesota) for virtual re-
onstruction of the ostia of the
eins in the last 20 patients. A
eflectable, circumferential deca-
o l a r m a p p i n g c a t h e t e r
LASSO, Biosense-Webster
nc., Baldwin Park, California)
as advanced into the left atrium
nd positioned at the ostium of
ach PV. A deflectable, 10.5-F
6.5-mm tip) cryoablation cathe-
er (CryoCor Inc., San Diego,
alifornia) was inserted into the
eft atrium through a 12-F, 65-
m-long sheath (DAIG, St. Jude Medical Inc., St. Paul,
innesota; or Cook Inc., Bloomington, Indiana).
Segmental isolation of PV guided by the recording of
heir potentials with the LASSO catheter was performed
sing the CryoCor cryoablation system as described previ-
usly (12). Efforts were made to identify the arrhythmo-
enic PV (culprit PV) using adenosine (24 to 40 mg)
Fig. 1) or isoproterenol (1 to 5 g). If the culprit PV(s)
ere not identified, all veins with potentials recorded at
heir ostium were targeted for ablation.
Isolation of the PV was performed during sinus rhythm
r coronary sinus pacing by delivering cryoablation at ostial
ites that had the earliest bipolar potential. Systematic
acing in the right superior PV region was performed before
pplication to access phrenic nerve capture.
At each effective target site, defined by the abolishment
f a PV potential or a change in the PV potential
ctivation sequence during cryothermal application, 3
in of cryoablation was delivered. If no changes in the
lectrogram were observed after 20 s, despite a catheter
ip temperature of 90°C, the application was stopped
nd the catheter repositioned. The early procedural end
oint was complete electrical isolation of PV based on
bolition of all ostial PV potentials or complete entrance
onduction block into the PV.
fter-ablation management. Every patient was monitored
n the hospital for 24 h and oral anticoagulation was
estarted the same day as the ablation. The same AAD were
ontinued for at least 3 months after the procedure. After
his period, the need for chronic anticoagulation was as-
essed by the amount of recurrences of AF and the presence
f risk factors for thromboembolic events.
All patients had a Holter recording at discharge and
uring each clinic visit (1, 3, 6, 9, and 12 months) or earlier
f they had symptoms. They were instructed to keep a diary
f events associated with their transtelephonic monitors. A
Abbreviations
and Acronyms
AAD  antiarrhythmic
drug(s)
CT  computed
tomography
PAF  paroxysmal atrial
fibrillation
PV  pulmonary vein(s)
PVI  pulmonary vein
isolation
RF  radiofrequency
TEE  transesophageal
echocardiogram
TTM  transtelephonic
telemetryisual analog scale ranging from zero (indicating no im-
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Long-Term Follow-Up After PV Cryoisolation February 26, 2008:850–5rovement at all) to 100 (asymptomatic and AF free after
VI) was used during the clinic visits.
Because of the logistics of the Maastricht area and the
resence of a dedicated research nurse (S.P.) who was
vailable to address patients’ concerns and questions at any
ime, we were able to follow every patient on an individual
asis and achieve a 90% compliance rate with daily TTM
t the end of 180 days.
To assess the presence of PV stenosis, serial CT scans of
he heart were performed at 3, 6 (63 patients), and 12
onths (12 patients). In 7 patients, a repeated CT scan was
ot performed on follow-up because of an allergic reaction
o the contrast agent on their baseline scan (n  3) and
atient refusal (n  4). A TEE was performed in those
ndividuals showing no increase in Doppler flow velocities
uggestive of PV stenosis.
The same radiologist (B.G.) reviewed all before- and
fter-cryoablation images in a blinded manner. The
iameter of the ostia of the PV was determined for each
atient in a pairwise manner to maintain consistency in
he measurements.
efinitions. Arrhythmogenic veins were considered those
hat, during AF, had a tachycardia cycle length shorter than
he one recorded in the coronary sinus catheter. Induction
f AF was attempted first by manipulation of the LASSO
atheter inside the vein (mechanical contact); if that did not
esult in arrhythmias, administrations of adenosine and
soproterenol infusion were used.
According to the 2007 Heart Rhythm Society/European
eart Rhythm Association/European Cardiac Arrhythmia
ociety expert consensus statement on catheter ablation of
F (13), an episode of AF detected by monitoring was
Figure 1 AF Initiated by a Trigger in the RSPV
An example of adenosine-induced atrial fibrillation (AF). HRA D  high right atriumonsidered a recurrence if it had a duration of 30 s or more. Ntatistical analysis. Continuous variables are presented as
ean  SD, where appropriate. In cases of a non-Gaussian
istribution, medians and quartiles are given. Categorical
ariables are expressed as numbers and percentages of patients.
A Kaplan-Meier analysis was used to determine the
ercentage of patients either free from AF (with or without
AD) or with 50% improvement after the index PVI.
esults
ur cohort consisted of 70 patients (54 men and 16 women)
ith PAF who fulfilled the described recruitment criteria of
he OPIPAF study.
The mean age was 40  10 years (range 21 to 65 years).
he mean duration of AF was 4  1 year. Patients had
ailed 1 to 2 AAD before PVI, and most of them had no
n 54 patients) or minimal heart disease (n 16 patients;
1 had arterial hypertension and 5 had a history of coronary
rtery disease). There was no history of amiodarone use.
The mean left atrial dimension was 38 2 (range 33 to 40)
m, with a mean left ventricular ejection fraction of 59 8%.
All targeted PV were successfully isolated (mean of 3 1
range 1 to 4] PV per patient). The following veins had
otentials and were isolated: left superior in 63 patients, left
nferior in 52 patients, right superior in 57 patients, and
ight inferior in 16 patients. The right inferior PV was
apped in 32 patients: one-half of them (16 patients) did
ot have any potentials in this vessel, whereas the other 16
atients had PV potentials that were ablated.
A total of 881 complete cryoapplications were given in
88 veins. A mean of 5 (range 1 to 13) applications were
iven per PV and 13 (range 3 to 23) applications per patient.
LSPV  left superior pulmonary vein; RSPV  right superior pulmonary vein.distal;o PV stenosis (accessed by serial spiral CT in 63 patients
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njury was detected during a mean follow-up of 33 15 (15
o 60) months.
Total procedure time averaged 331 min and fluoroscopy
ime 88 min. Our long procedure times during PVI are in
art due to extensive pacing/pharmacologic maneuvers and
ther interventions that we used while trying to induce
rrhythmias and access end points.
Thirty-four patients (49%) had no AF recurrences with-
ut AAD, 15 patients (22%) had no AF recurrences with
AD, and 8 patients (11%) with sporadic AF bursts
eported an improvement of 50% with AAD after the
blation. Overall, 82% of patients benefited from the pro-
edure after the index PVI (Fig. 2). Of the 13 patients who
id not improve, 10 had a second PVI 6 months after the
rst procedure. Of those patients, 6 had much improvement
n their symptoms. Three patients remained with symptom-
tic AF and opted for rate control. In 1 patient, a third
rocedure was needed to ablate a focal tachycardia coming
rom the left inferior PV. He became asymptomatic.
Figure 2 Kaplan-Meier Curve Showing the Outcomes of Pulmon
After a mean follow-up of 33  15 months, pulmonary vein cryoisolation was effec
who, at any time, reported 50% improvement. The table shows the number of evIn only 10 patients (14%), the arrhythmogenic PV(s) could
e identified using the criterion of a higher AF rate in the PV
han in the coronary sinus or adenosine administration (Fig. 1).
hen compared with the rest of the cohort, we found no
tatistically significant differences in their clinical characteristics
sing t tests or chi-square tests. The characteristics were
istributed as follows: one patient had 3 different arrhythmo-
enic veins, 7 patients had 2 arrhythmogenic veins, and 2
atients had only 1 arrhythmogenic vein. In those patients, no
ecurrences were observed during long-term follow-up.
omplications. Complications were seen in 3 patients
4%). One of our first patients had a cerebral ischemic event
ith left-sided hemiplegia occurring at the end of the
rocedure. Factors other than the energy source could have
layed a role in this event (such as problems with antico-
gulation, several exchanges of the sheaths, or long proce-
ure time) Subsequently, this patient recovered all his
aseline function.
A second patient developed a pulmonary embolism 2
onths after the ablation (when he was also found to be
ein Cryoisolation
82% of patients. An event was considered a patient
ompared with patients at risk over time. AF  atrial fibrillation.ary V
tive in
ents c
i
a
c
d
t
s
D
M
a
p
A
i
a
a
p
a
b
C
a
b
t
o
c
u
l
i
o
f
s
s
m
l
a
a
t
A
R
d
F
A
P
p
l
s
i
(
b
a
t
o
fi
m
P
a
e
A
p
o
p
s
t
S
o
2
p
d
r
d
c
c
c
o
t
c
l
B
l
t
v
p
m
C
I
h
w
3
w
c
(
i
(
P
p
R
g
P
854 Moreira et al. JACC Vol. 51, No. 8, 2008
Long-Term Follow-Up After PV Cryoisolation February 26, 2008:850–5nadequately anticoagulated). Although we cannot directly
ssociate this event with the cryoablation, we decided to
ount it as an adverse effect during our follow-up.
The third patient had transient phrenic nerve paralysis
uring the application in the right superior PV. However,
he diaphragmatic movement recovered immediately after
topping the cryoapplication.
iscussion
ain findings. Our study shows that a more localized
blation strategy using cryothermy is effective in 82% of
atients with PAF: 49% without AF recurrences without
AD, 22% without AF while receiving AAD, and 11%
mproved 50% with AAD (sporadic bursts of AF) during
mean follow-up of 33  15 (range 15 to 60) months. The
cute complications seen (stroke and transient phrenic nerve
aralysis) were within the acceptable range for the procedure
nd did not result in long-term limitations for the patients.
In those patients in whom the arrhythmogenic PV could
e identified and isolated, no recurrences were observed.
ryothermy is effective as an energy source in AF
blation. Our study shows that 82% of patients with PAF
enefited from pulmonary vein cryoisolation during long-
erm follow-up (Fig. 2). Those results are similar to those
btained with RF (14–19). However, in comparison to RF,
ryothermy may have some advantages.
Cryoenergy causes adherence of the catheter tip to the
nderlying tissue during energy delivery, ensuring accurate
esion creation (20–22). This might be important in avoid-
ng catheter dislocation to areas where complications could
ccur (such as the posterior left atrium or inside the PV).
Cryoenergy also has the ability to create reversible loss of
unction, allowing the prediction of the effectiveness and
afety of a lesion (23,24). It does not require conscious
edation or anesthesia, as it is painless (25). This not only
eans more comfort for the patients but also decreases the
ow but real complications of anesthesia.
Cryothermal ablation preserves the extracellular matrix
nd endothelial integrity. As a result, it had not been
ssociated with PV stenosis, esophageal perforation, or
hromboembolic events during the treatment of AF (26,27).
lthough the rate of thromboembolic complications during
F ablation of AF is small, such consequences could be
readful in a relatively young and healthy population.
ocal approach versus large lesions in the treatment of
F. All patients in whom we were able to identify which
V was the trigger were cured. Our relatively healthy
opulation (no or minimal structural heart disease, normal
eft atrial dimension, or PAF) could represent the early
tages of AF. At this time, ablation of potential triggers
nstead of isolation of all PV should be preferred.
A study by Nanthakumar et al. (28) showed that adolescents
without structural heart disease) referred for ablative therapy
ecause of lone AF have an excellent outcome with the focal
blation of distinct foci (most located in the PV). Owing to
Eheir age, this population could really represent the first stages
f AF, and the success in their treatment corroborates our
ndings of a more localized approach in a healthier population.
Gerstenfeld et al. (29) have shown a good long-term (18
onths) outcome in patients younger than 50 years with
AF undergoing targeted ablation of 2 PV with triggered
trial premature beats or AF. Also, a recent report by Oral
t al. (30) using a tailored approach to catheter ablation of
F has shown an 80% success rate despite having 40% of
atients with evidence of structural heart disease. Although
ne could say that the group’s study population had already
assed the first stages of AF, their results again ratify the
uccess of limited electrophysiologically guided lesions in
he percutaneous treatment of arrhythmias.
tudy limitations. Our daily TTM recorded only fractions
f the day and do not represent cardiac rhythm during a
4-h period. Continuous rhythm monitoring would be
referable, but it would be hard to justify implanting a
evice in this healthy population. After 180 days, we
eturned to a symptom-guided recording method, which
espite being widely used has some disadvantages (poor
orrelation between symptoms and arrhythmias was shown
onsistently in 2 studies) (31,32).
Despite being around for a long time in the surgical field,
atheter-based cryoablation is still a relatively new technol-
gy compared to RF. Also, efficiency is highly dependent on
he duration of application and pressure against the myo-
ardial tissues (33,34). This could lead to the concept of
onger procedure times when comparing cryoablation to RF.
ut if we consider total time in the electrophysiology
aboratory (including time devoted to anesthesia), cryo-
hermy and RF procedures are not that different.
Also the identification of an arrhythmogenic PV was not
ery frequent. In our population, it was identified in only 10
atients (14%). Unfortunately, this represents the reality of
ost patients with PAF submitted to PVI (29,30).
onclusions
n patients with recent-onset PAF and no (or minimal) structural
eart disease, PV cryoisolation is effective in 82% of patients: 49%
ith complete success (no AF and no AAD) and an additional
3% with improvement (22% AF-free with AAD and 11%, still
ith sporadic bursts of AF, reporting 50% improvement
ompared to before ablation) during long term follow-up
mean of 33 15 months). When the arrhythmogenic PV is
dentified and isolated, the long-term outcome is excellent
100% freedom from AF), indicating no need to isolate all
V. Pulmonary vein isolation alone should be performed in
atients early in the process of the disease.
eprint requests and correspondence: Dr. Luz-Maria Rodri-
uez, Department of Cardiology, Academic Hospital Maastricht,
. Debyelaan 25, P.O. Box 5800, Maastricht, the Netherlands.
-mail: lm.rodriguez@cardio.unimaas.nl.
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